Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Farmers Insurance
Dow
AstraZeneca
Argus Health
Covington
Boehringer Ingelheim
UBS
Johnson and Johnson
Queensland Health

Generated: August 21, 2017

DrugPatentWatch Database Preview

RAPAMUNE Drug Profile

« Back to Dashboard

What is the patent landscape for Rapamune, and what generic Rapamune alternatives are available?

Rapamune is a drug marketed by Pf Prism Cv and is included in two NDAs. There is one patent protecting this drug and two Paragraph IV challenges.

The generic ingredient in RAPAMUNE is sirolimus. There are eighteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the sirolimus profile page.

Summary for Tradename: RAPAMUNE

Patents:1
Applicants:1
NDAs:2
Suppliers / Packagers: see list3
Bulk Api Vendors: see list42
Clinical Trials: see list99
Patent Applications: see list9,757
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:RAPAMUNE at DailyMed

Pharmacology for Tradename: RAPAMUNE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-004Jan 25, 2010ABRXYesNo► Subscribe► SubscribeY► Subscribe
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-003Feb 23, 2004DISCNYesNo► Subscribe► SubscribeY► Subscribe
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-001Aug 25, 2000ABRXYesNo► Subscribe► Subscribe► Subscribe
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-003Feb 23, 2004DISCNYesNo► Subscribe► Subscribe► Subscribe
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-004Jan 25, 2010ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: RAPAMUNE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-001Aug 25, 2000► Subscribe► Subscribe
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-001Aug 25, 2000► Subscribe► Subscribe
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-003Feb 23, 2004► Subscribe► Subscribe
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-002Aug 22, 2002► Subscribe► Subscribe
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-004Jan 25, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: RAPAMUNE

Drugname Dosage Strength RLD Submissiondate
sirolimusTablets0.5 mgRapamune8/25/2010
sirolimusTablets1 mg and 2 mgRapamune12/17/2009
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Argus Health
Moodys
Express Scripts
McKesson
Boehringer Ingelheim
Novartis
Harvard Business School
Merck
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot